ALKEM LABORATORIES LTD.

Manufactures and sells pharmaceutical formulations in India and overseas, with FY26 consolidated revenue of Rs 14,712.27 crore growing 13.5 percent year-on-year. Domestic branded generics form the core; the standalone Indian business contributed Rs 9,664 crore in turnover, while international operations grew 22.5 percent. The company launched semaglutide, a GLP-1 drug used in type-2 diabetes and weight management, priced from Rs 350 per unit, and was the first in India to offer it in single-shot pre-filled syringes; biosimilars are nearing European launch. To diversify beyond formulations, it acquired a 51-55 percent stake in Switzerland-based Occlutech Holding AG for Euro 99.4 million through wholly owned subsidiary Alkem Medtech, entering cardiovascular and orthopedic medical devices, and completed the Bombay Ortho acquisition. A scheme to amalgamate wholly owned Adroit Biomed is before the NCLT. Materials account for 24.2 percent of revenue, employees 19.3 percent, other operating expenses 25.7 percent, and EBITDA margin is 23.2 percent. AR · MarketPing reader · 2026-08-02

Revenue streams, as the annual report describes them. Domestic branded generics (India), International pharmaceutical business, MedTech (cardiovascular and orthopedic devices). Diversifying Indian pharmaceutical company - branded generics domestically, growing international business, expanding into MedTech and biosimilars.

Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)